Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00104572 · ClinicalTrials.gov registry record · Phase 2

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

A Phase 2 study, sponsored by National Institute on Aging (NIA).

Completed
Registry status
Phase 2
Development phase
44
Enrollment target

NCT00104572: Completed Phase 2 study, sponsored by National Institute on Aging (NIA).

NCT00104572 is a Phase 2 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00104572, a Phase 2 study, has completed, sponsored by National Institute on Aging (NIA).

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target

Study Summary

Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body. This is associated with negative effects on muscle strength, bone density, sexual function, mood, and the ability to think to the best of one's ability. Testosterone replacement therapy often involves injections, patches, or gels that help to raise circulating testosterone levels, but these therapies often have side effects because they lead to imbalance of other hormones. Researchers have been studying the effectiveness of anastrozole, a drug that can lower estrogen levels while simultaneously increasing testosterone levels, as a treatment for the negative effects of decreased circulating testosterone levels that occur naturally with aging. Objectives: To evaluate whether anastrozole is as effective as testosterone gel in improving bone and muscle strength, hormone levels, and brain function in men over 65 years of age. Eligibility: Healthy men at least 65 years of age who have low levels of testosterone. Design: The study involves six study visits over a total of 12 months: screening, baseline, 6 weeks, 3 months, 6 months, and 12 months. All participants will receive calcium and vitamin D supplements to take daily, and will be randomized to one of three groups:Testosterone gel and placebo tablet, Anastrozole tablet and placebo gel, Placebo tablet and gel. Participants will have the following tests at each specified visit:Screening: Blood tests and rectal ultrasound to evaluate the prostate;Baseline: Blood and urine tests; growth hormone levels, muscle strength, bone density, and balance evaluation; imaging studies; cognitive testing; and questionnaires on quality of life, sexual function, depression, and urinary symptoms;Six weeks: Blood tests and dose adjustment of the gel or tablet;Three months: Blood and urine tests; growth hormone, muscle strength, bone density, and balance evaluation; and questionnaires on quality of

Primary Outcome

bone mineral density lumbar spine for all arms testosterone gel, anastrozole and placebo

Interventions

  • DRUG Placebo tablet
  • DRUG Placebo gel
  • DRUG Androgel (Testosterone Gel)
  • DRUG Anastrozole (Aromatase Inhibitor)
  • DIETARY_SUPPLEMENT Calcium Cardone 500mg with vitamin D 400 IU

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2004-03
Est. Completion 2015-01
Phase Phase 2
National Institute on Aging (NIA)

131 total trials

What the finished NCT00104572 record still lists

NCT00104572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 5 interventions - of which Placebo tablet is the first listed.

NCT00104572 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00104572 about?

NCT00104572 is a clinical study titled "Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.". Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body. This is associated with negative effects on muscle strength, bone density, sexual function, mood, and the ability to think to the best of one's ability. Tes...

What is the current status of trial NCT00104572?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2004-03. Estimated completion is 2015-01.

What interventions are being tested in trial NCT00104572?

The interventions under investigation include: Placebo tablet (DRUG), Placebo gel (DRUG), Androgel (Testosterone Gel) (DRUG), Anastrozole (Aromatase Inhibitor) (DRUG), Calcium Cardone 500mg with vitamin D 400 IU (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00104572?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00104572's enrollment target sits among peer trials

44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00104572, the US trial registry maintained by the National Library of Medicine. NCT00104572 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.